News | June 03, 2021
Lupin announces U.S. FDA acceptance for pegfilgrastim biosimilar application
Pegfilgrastim has estimated annual sales of USD 3.66 billion in the U.S. (IQVIA MAT December 2020).
Pegfilgrastim has estimated annual sales of USD 3.66 billion in the U.S. (IQVIA MAT December 2020).
Sun Pharma is granted rights for co-marketing of the drug in India in the private market under the brand name CARITEC
Consequently, AstraZeneca India and Sun Pharma have now discontinued the Distribution Agreement signed in 2016 and have entered into a Transition Supply Agreement with effect from 28th May 2021
With the surge of infections in India in the recent days AmphoTLC will address the country's acute liposomal amphotericin B shortage
Allecra Therapeutics would now either directly or through out license file for NDA of this molecule.
We focused on developing the product last year but now our focus is on ramping up our manufacturing capacity
Natco has withdrawn its application filed with the Indian Patent Office, seeking Compulsory License against Lilly for Baricitinib for Covid-19 in India
Number of approved manufacturing sites of Remdesivir in the country has increased from 22 sites to 60
The deal is to sell one of the two business undertakings of ZAHL for a lump sum consideration of Rs. 2921 crores on a cash free and debt free basis,
The agreement will help ensure wider reach and access to patients in India
Subscribe To Our Newsletter & Stay Updated
